William Funk
Family Medicine · Newark, DENPI 1598796286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,598 and has fallen 94.7% since, to $85 in 2024.
Across 312 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$904
- Lilly USA, LLC$545
- Merck$452
- Boehringer Ingelheim$320
- AbbVie$316
- Pfizer$288
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,53397%
- Education$1883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $904 |
| Lilly USA, LLC | 42 | $545 |
| Merck | 27 | $452 |
| Boehringer Ingelheim | 17 | $320 |
| AbbVie(2 entities) | 18 | $316 |
| Pfizer | 15 | $288 |
| Johnson & Johnson | 12 | $287 |
| Esperion Therapeutics, Inc. | 11 | $252 |
| Astellas Pharma US Inc | 8 | $243 |
| Amgen | 13 | $230 |
| Novo Nordisk | 8 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $172 |
| Teva Pharmaceuticals USA, Inc. | 12 | $165 |
| Bayer | 6 | $126 |
| Avanir Pharmaceuticals, Inc. | 2 | $126 |
| Sanofi Pasteur Inc. | 7 | $125 |
| Jazz Pharmaceuticals Inc. | 6 | $115 |
| Eisai Inc. | 7 | $107 |
| Adlon Therapeutics L.p. | 5 | $87 |
| Genentech USA, Inc. | 5 | $87 |
| GSK | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $66 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| VBI Vaccine (delaware) Inc. | 2 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Lundbeck LLC | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Shire North American Group Inc | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Seqirus USA Inc | 2 | $29 |
| Corium, LLC | 1 | $25 |
| Abbott | 2 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,721 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 14 | $598 |
| Losartan Potassium | 31 | $356 |
| Rosuvastatin Calcium | 16 | $327 |
| Atorvastatin Calcium | 24 | $277 |
| Amlodipine Besylate | 17 | $92 |
| Lisinopril | 12 | $80 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Ian MyersNewark$17K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Arlen StoneNewark$10K
- Imelyn LaheyNewark$8K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.